M&A Deal Summary

Keensight Capital Acquires Symeres

On May 25, 2021, private equity firm Keensight Capital acquired life science company Symeres from Gilde Healthcare

Acquisition Highlights
  • This is Keensight Capital’s 4th transaction in the Life Science sector.
  • This is Keensight Capital’s 2nd transaction in the Netherlands.

M&A Deal Summary
Date 2021-05-25
Target Symeres
Sector Life Science
Buyer(s) Keensight Capital
Sellers(s) Gilde Healthcare
Deal Type Secondary Buyout

Target

Symeres

Nijmegen, Netherlands
Symeres is a mid-sized European Contract Research Organization for drug discovery and development needs. The company offers best-in-class solutions for drug discovery and drug development for small molecules and beyond. Their services span from preclinical hit finding all the way to the delivery of early clinical phase drug substance API. Symeres blends a deep scientific knowledge base with creativity and problem-solving skills to deliver the quality results that clients need. Symeres is based in Nijmegen, Netherlands.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Keensight Capital

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2000
PE ASSETS 5.5B EUR
Size Mega
Type Sector Agnostic
DESCRIPTION

Keensight Capital is a private equity investment firm focused on majority and minority growth capital investments in Western European companies. Keensight makes equity investments in a number of situations including the provision of capital to finance growth, either organically or through acquisitions, or the buying out of existing shareholders. The Firm looks to invest €10 to €600 million and will consider business with up to €400 million in revenue. Keensight Capital was formed in 2000 and is based in Paris.

DEAL STATS #
Overall 31 of 50
Sector (Life Science) 4 of 9
Type (Secondary Buyout) 5 of 11
Country (Netherlands) 2 of 5
Year (2021) 2 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-05-11 Linkbynet

Saint-Denis, France

Linkbynet is a provider of cloud computing and security. Linkbynet was founded in 2000 and is based in Saint-Denis, France.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-06-15 Inherent

Maxéville, France

Inherent is a specialist in IT and telecom services, supports the digitalisation of a diverse customer base, made up of private-sector players (from SMEs to large companies) and public-sector organisations (hospitals and local authorities), with a full range of services. Inherent was founded in 1981 and is based in Maxéville, France.

Buy -

Seller(S) 1

SELLER

Gilde Healthcare

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 1999
PE ASSETS 2.6B EUR
Size Large
Type Sector Focused
DESCRIPTION

Gilde Healthcare is a specialist private equity and venture investor focused on the healthcare sector. The Firm's buyout group targets majority investments throughout Europe (preference for Germany, the Netherlands, Belgium, Austria or Switzerland) and has a focus on healthcare providers, suppliers and service providers active in the healthcare market. The Firm's venture group looks to invest in early stage medtech, diagnostics, digital health and therapeutics companies throughout North America and Europe. Gilde Healthcare was established in 2001 and is headquartered in Utrecht, the Netherlands.

DEAL STATS #
Overall 27 of 30
Sector (Life Science) 15 of 16
Type (Secondary Buyout) 5 of 5
Country (Netherlands) 9 of 10
Year (2021) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-05-06 KLIFO

Glostrup, Denmark

KLIFO is a drug development consultancy with significant experience in partnering with biotech and pharmaceutical companies to advance their drug development projects. KLIFO provides end-to-end expert capabilities, enabling partners to maximize opportunity, mitigate risks, drive innovation and achieve efficient project advancement. KLIFO was founded in 1994 and is based in Glostrup, Denmark.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-11-22 Laboratoris Sanifit

Palma de Mallorca, Spain

Laboratoris Sanifit is a clinical-stage biopharmaceutical company focused on the development of SNF472, a promising drug for the treatment of cardiovascular diseases linked to calcification in patients with End Stage Renal Disease (ESRD) undergoing hemodialysis. Laboratoris Sanifit was founded in 2004 and is based in Palma de Mallorca, Spain.

Sell €205M
Mergr

Product

Company

Legal